Triazole compound having novel ring structure, method for preparing same, and use thereof
Novel ring-structured triazole compounds effectively inhibit ASK1, addressing the need for cell-penetrating ASK1 inhibitors by offering robust neuroprotection in ASK1-related diseases like Parkinson's, enhancing dopaminergic neuron survival and reducing microglial activation.
Patent Information
- Application Number
- PCT/KR2024/010056
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-07-12
- Filing Date
- 2024-07-12
- Publication Date
- 2025-01-16
AI Technical Summary
Current treatments for ASK1-related diseases, such as Parkinson's and autoimmune disorders, lack effective inhibitors that can penetrate cell membranes and provide significant neuroprotection without being substrates for efflux transporters.
Development of novel ring-structured triazole compounds that inhibit ASK1, allowing for effective penetration into cells and offering neuroprotection while avoiding efflux transporters, thereby treating ASK1-related diseases.
The novel triazole compounds demonstrate high ASK1 inhibitory activity, providing significant neuroprotection and improving symptoms in models of Parkinson's disease and other ASK1-related conditions, including increased dopaminergic neuron survival and reduced microglial activation.
Smart Images

Figure KR2024010056_16012025_PF_FP_ABST
Abstract
Description
Triazole compound with a novel ring structure, preparation method thereof, and use thereof
[0001] The present invention relates to a novel triazole compound having a ring structure, a method for preparing the same, and a use thereof.
[0002] Apoptosis signal-regulating kinase 1 (ASK1), also known as MAP3K5, is a member of the c-Jun N-terminal protein kinase (JNK) and stress-responsive mitogen-activated protein kinase (MAP3K) family. ASK1 is a central regulator of apoptosis and is known to participate in several stress-induced and receptor-mediated cell death pathways triggered by various forms of stress, including oxidative stress, reactive oxygen species (ROS), endoplasmic reticulum (ER) stress and unfolded protein response (UPR), and mitochondrial stress.
[0003] Furthermore, ASK1 plays an essential role not only in the apoptotic pathway but also in inflammatory and innate immune responses, including cytokine responses and cell differentiation. Phosphorylation of ASK1 protein can induce apoptosis or other cellular responses, depending on the cell type. In particular, ASK1 activation and signaling have been reported to play a crucial role in a wide range of diseases, including neurodegenerative, cardiovascular, inflammatory, autoimmune, and metabolic diseases. Furthermore, ASK1 is known to be involved in mediating organ damage following ischemia and reperfusion in the heart, brain, and kidney (Zhang et al. J Clin Invest. 2003; 111(12): 1933-1943.).
[0004] Meanwhile, Parkinson's disease is a neurodegenerative disease that primarily occurs in the elderly. Parkinson's disease is caused by the death of dopaminergic neurons in the substantia nigra, a region in the brain's center, leading to behavioral disturbances. Furthermore, Lewy bodies, formed by the deposition of alpha-synuclein proteins in various regions of the brain and peripheral nerves, are a key neuropathological characteristic of Parkinson's disease. Representative symptoms of Parkinson's disease include bradykinesia (abnormal slowing of body movements), tremor (shaking of the hands and feet), and rigidity (stiffening of muscles and joints). Non-motor symptoms include mental disorders and autonomic dysfunction.
[0005] At this time, it has been reported that excessive amounts of ASK1 are closely related to heart disease, inflammatory diseases, liver disease, infectious diseases, and degenerative brain diseases, and the possibility of ASK1 inhibition as a treatment for Parkinson's disease is being raised from various angles. When Parkinson's disease was induced by alpha-synuclein pre-formed fibrils (PFF), the accumulation of phosphorylated alpha-synuclein (p-alpha-synuclein) in the striatum and cerebral cortex was reduced in ASK1-deficient mice. Furthermore, neuroinflammation was also alleviated, which led to behavioral improvements. In addition, p-ASK1 activation was observed to be more than four times higher in neurons in the substantia nigra of Parkinson's disease patients compared to normal individuals.
[0006] Accordingly, the inventors of the present invention completed the present invention by confirming, in the course of studying ASK1 derivatives, that a novel triazole compound has excellent ASK1 inhibitory activity while protecting nerve cells, easily permeates cell membranes, and is not an efflux transporter.
[0007] One object of the present invention is to provide a trihazol compound having a novel ring structure.
[0008] One object of the present invention is to provide a method for preparing a triazole compound having a novel ring structure.
[0009] One object of the present invention is to provide a pharmaceutical composition containing a triazole compound having a novel ring structure as an active ingredient.
[0010] One object of the present invention is to provide a pharmaceutical composition for preventing or treating ASK1-related diseases, which contains a triazole compound having a novel ring structure as an active ingredient.
[0011] One object of the present invention is to provide a method for preventing or treating an ASK1-related disease, comprising administering to a subject a triazole compound having a novel ring structure.
[0012] One object of the present invention is to provide a novel cyclic structure triazole compound for use in the prevention or treatment of ASK1-related diseases.
[0013] One object of the present invention is to provide a use of a novel triazole compound having a ring structure for preparing a medicament for preventing or treating an ASK1-related disease.
[0014] According to one aspect of the present invention, a compound represented by the following chemical formula 1, a stereoisomer thereof, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof is provided:
[0015] [Chemical Formula 1]
[0016]
[0017] In the above chemical formula 1,
[0018] is unsubstituted or substituted phenyl or unsubstituted or substituted C 3-8 It is cycloalkenyl,
[0019] The above substituted phenyl and substituted C 3-8 Each cycloalkenyl is independently C 1-6 Alkyl, C 1-6 substituted with alkoxy or halogen;
[0020] R1, R2 and R3 are each independently H, C 1-6Alkyl, halogen, C 3-6 Cycloalkyl or haloC 1-6 It's alkyl.
[0021] According to one aspect of the present invention, a method for producing a compound represented by Chemical Formula 1 of claim 1 is provided, which comprises the step of producing a compound represented by Chemical Formula 1 by reacting a compound represented by Chemical Formula 2 with a compound represented by Chemical Formula 3, as shown in the following reaction scheme 1:
[0022] [Reaction Formula 1]
[0023]
[0024] In the above reaction formula 1 , R1, R2, and R3 are as defined in the above chemical formula 1.
[0025] According to one aspect of the present invention, a pharmaceutical composition for preventing or treating an ASK1-related disease is provided, which contains a compound represented by the above chemical formula 1, a stereoisomer thereof, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof as an active ingredient.
[0026] According to one aspect of the present invention, a method for preventing or treating an ASK1-related disease is provided, comprising administering to a subject a pharmaceutical composition containing a compound represented by the above chemical formula 1, a stereoisomer thereof, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof as an active ingredient.
[0027] According to one aspect of the present invention, there is provided a use of a pharmaceutical composition containing a compound represented by the above chemical formula 1, a stereoisomer thereof, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment of an ASK1-related disease.
[0028] According to one aspect of the present invention, there is provided a use of a pharmaceutical composition containing a compound represented by the above chemical formula 1, a stereoisomer thereof, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof for preparing a medicament for preventing or treating an ASK1-related disease.
[0029] The novel triazole compound of the present invention having a cyclic structure exhibits a high inhibitory activity against ASK1 and suppresses the death of nerve cells, and therefore can be used for the prevention or treatment of ASK1-related diseases, including neurodegenerative diseases, cardiovascular diseases, and autoimmune diseases. For example, the compound of the present invention can effectively prevent or treat Parkinson's disease by improving behavioral defects or errors and neurological disorder symptoms associated with Parkinson's disease, significantly improving dopaminergic neurodegeneration, and reducing microglia. In addition, the compound of the present invention can effectively prevent or treat amyotrophic lateral sclerosis by improving neurological disorders or disease symptoms and decreased grip strength associated with amyotrophic lateral sclerosis and increasing survival rate. In addition, the compound of the present invention can effectively prevent or treat fibromyalgia by improving pain associated with fibromyalgia. In addition, the compound of the present invention can effectively prevent or treat nonalcoholic steatohepatitis by improving liver fibrosis associated with nonalcoholic steatohepatitis.
[0030] Figure 1 shows the cell protection effect (% of control) by evaluating the neuroprotection assay.
[0031] Figure 2 shows the cell viability (%) and TNF-α ELISA results of LPS-treated cells.
[0032] Figure 3 is a schematic diagram of an experiment to confirm the efficacy of a drug in an MPTP-induced PD mouse model.
[0033] Figure 4 is a graph showing the results of a behavioral deficit evaluation (pole test) by group according to drug administration in an MPTP-induced PD mouse model. Here, a, b, and c represent the rotation time at the top, the time to descend the pole, and the total time, respectively. Significance level compared to G1 - *: p < 0.05, **: p < 0.01, ***: p < 0.001 / Significance level compared to G2 - #: p < 0.05, ##: p < 0.01, ###: p < 0.001.
[0034] Figure 5a is a graph showing the degree of TH staining in the striatum by group according to drug treatment in an MPTP-induced PD mouse model. Significance level compared to G1 - *: p < 0.05, **: p < 0.01, ***: p < 0.001 / Significance level compared to G2 - #: p < 0.05, ##: p < 0.01, ###: p < 0.001.
[0035] Figure 5b is an image showing the degree of TH staining in the striatum by group according to drug treatment in the MPTP-induced PD mouse model.
[0036] Figure 6a is a graph showing the degree of TH staining in the substantia nigra according to drug treatment in an MPTP-induced PD mouse model. Significance level compared to G1 - *: p < 0.05, **: p < 0.01, ***: p < 0.001 / Significance level compared to G2 - #: p < 0.05, ##: p < 0.01, ###: p < 0.001.
[0037] Figure 6b is an image showing the degree of TH staining in the substantia nigra by group according to drug treatment in an MPTP-induced PD mouse model.
[0038] Figure 7 is a graph showing the dopamine concentrations in the striatum and substantia nigra of an MPTP-induced PD mouse model according to drug treatment by group. Significance level compared to G1 - *: p < 0.05, **: p < 0.01, ***: p < 0.001 / Significance level compared to G2 - #: p < 0.05, ##: p < 0.01, ###: p < 0.001.
[0039] Figure 8 is a schematic diagram of an experiment to confirm the efficacy of a drug in an α-Syn transgenic Parkinson's disease mouse model.
[0040] Figure 9 is a graph showing the change in body weight by group according to drug treatment in an α-Syn transgenic Parkinson's disease mouse model. Significance level compared to G1 - *: p < 0.05, **: p < 0.01, ***: p < 0.001 / Significance level compared to G2 - #: p < 0.05, ##: p < 0.01, ###: p < 0.001.
[0041] Figure 10 is a graph of neurological behavioral scores by group according to drug treatment in an α-Syn transgenic Parkinson's disease mouse model. Significance level compared to G1 - *: p < 0.05, **: p < 0.01, ***: p < 0.001 / Significance level compared to G2 - #: p < 0.05, ##: p < 0.01, ###: p < 0.001.
[0042] Figure 11 is a graph showing the results of gait error evaluation by group according to drug treatment in an α-Syn transgenic Parkinson's disease mouse model. Significance level compared to G1 - *: p < 0.05, **: p < 0.01, ***: p < 0.001 / Significance level compared to G2 - #: p < 0.05, ##: p < 0.01, ###: p < 0.001.
[0043] Figure 12a is a graph showing the results of an evaluation of the efficacy of drug treatment on improving dopaminergic neurodegeneration by group in an α-Syn transgenic Parkinson's disease mouse model. Significance level compared to G1 - *: p < 0.05, **: p < 0.01, ***: p < 0.001 / Significance level compared to G2 - #: p < 0.05, ##: p < 0.01, ###: p < 0.001.
[0044] Figure 12b is an immunofluorescence analysis image showing the results of evaluating the efficacy of improving dopaminergic neurodegeneration by group according to drug treatment in an α-Syn transgenic Parkinson's disease mouse model.
[0045] Figure 13a is a graph showing the results of the evaluation of the efficacy of drug treatment on reducing microglial counts by group in an α-Syn transgenic Parkinson's disease mouse model. Significance level compared to G1 - *: p < 0.05, **: p < 0.01, ***: p < 0.001 / Significance level compared to G2 - #: p < 0.05, ##: p < 0.01, ###: p < 0.001.
[0046] Figure 13b is an immunofluorescence analysis image showing the results of evaluating the efficacy of reducing microglial cells by group according to drug treatment in an α-Syn transgenic Parkinson's disease mouse model.
[0047] Figure 14 is a schematic diagram of an experiment to confirm the efficacy of a drug in a SOD1 G93A transgenic ALS mouse model.
[0048] Figure 15 is a graph showing changes in body weight by group according to drug treatment in the SOD1 G93A transgenic ALS mouse model. Significance level compared to G1 - *: p < 0.05, **: p < 0.01, ***: p < 0.001.
[0049] Figure 16 is a graph of neurological scores by group according to drug treatment in an SOD1 G93A transgenic ALS animal model. Significance level compared to G1 - *: p < 0.05, **: p < 0.01, ***: p < 0.001 / Significance level compared to G2 - #: p < 0.05, ##: p < 0.01, ###: p < 0.001.
[0050] Figure 17 is a graph showing changes in disease scores by group according to drug treatment in the SOD1 G93A transgenic ALS mouse model. Significance level compared to G1 - *: p < 0.05, **: p < 0.01, ***: p < 0.001 / Significance level compared to G2 - #: p < 0.05, ##: p < 0.01, ###: p < 0.001.
[0051] Figure 18 is a graph showing changes in grip strength by group according to drug treatment in the SOD1 G93A transgenic ALS mouse model. Significance level compared to G1 - *: p < 0.05, **: p < 0.01, ***: p < 0.001 / Significance level compared to G2 - #: p < 0.05, ##: p < 0.01, ###: p < 0.001.
[0052] Figure 19 is a graph showing the survival rate by group according to drug treatment in the SOD1 G93A transgenic ALS mouse model.
[0053] Figure 20 is a schematic diagram of an experiment to confirm the efficacy of a drug in a reserpine-induced fibromyalgia rat model.
[0054] Figure 21 is a graph showing the results of an evaluation of pain improvement efficacy according to drug treatment in a reserpine-induced fibromyalgia rat model. Significance level compared to G1 - *: p < 0.05, **: p < 0.01, ***: p < 0.001 / Significance level compared to G2 - #: p < 0.05, ##: p < 0.01, ###: p < 0.001.
[0055] Figure 22 is a schematic diagram of an experiment to confirm the efficacy of a drug in a CDAHFD-induced non-alcoholic steatohepatitis mouse model.
[0056] Figure 23a is a graph showing the ratio of Picrosirius red staining area in the liver according to drug treatment in a CDAHFD-induced nonalcoholic steatohepatitis mouse model. Significance level compared to G1 - *: p < 0.05, **: p < 0.01, ***: p < 0.001 / Significance level compared to G2 - #: p < 0.05, ##: p < 0.01, ###: p < 0.001.
[0057] Figure 23b is an image of the Picrosirius red staining area ratio in the liver according to drug treatment in a CDAHFD-induced non-alcoholic steatohepatitis mouse model.
[0058] One aspect of the present invention provides a compound represented by the following chemical formula 1, a stereoisomer thereof, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof.
[0059] [Chemical Formula 1]
[0060]
[0061] In the above chemical formula 1,
[0062] is unsubstituted or substituted phenyl or unsubstituted or substituted C 3-8 It is cycloalkenyl,
[0063] The above substituted phenyl and substituted C 3-8 Each cycloalkenyl is independently C 1-6 Alkyl, C 1-6 substituted with alkoxy or halogen;
[0064] R1, R2 and R3 are each independently H, C 1-6 Alkyl, halogen, C 3-6 Cycloalkyl or haloC 1-6 It's alkyl.
[0065] Also, in the above chemical formula 1,
[0066] is unsubstituted or substituted phenyl or unsubstituted or substituted C 5-8 It is cycloalkenyl,
[0067] The above substituted phenyl and substituted C 3-8 Each cycloalkenyl is independently C 1-3 Alkyl, C 1-3 substituted with alkoxy or halogen;
[0068] R1, R2 and R3 are each independently H, C 1-3 Alkyl, halogen, C 3-6 Cycloalkyl or haloC 1-3 It's alkyl.
[0069] Also, in the above chemical formula 1,
[0070] C containing one phenyl or double bond 5-8 It is cycloalkenyl;
[0071] R1 is C 3-6 It is cycloalkyl,
[0072] R2 is C 1-3 It is alkyl,
[0073] R3 is a halogen.
[0074] Also, in the above chemical formula 1,
[0075] C containing one phenyl or double bond 5-8 It is cycloalkenyl;
[0076] R1 is cyclopropyl,
[0077] R2 is methyl,
[0078] R3 is fluoro.
[0079] The term “cycloalkenyl” as used herein includes any stable cyclic hydrocarbon group, which contains one or more unsaturated carbon-carbon double bonds at any position of the ring, may be mono- or polysubstituted, and may be monovalent, divalent, or polyvalent. In the present specification, it is divalent fused to a triazole. Examples of embodiments of such cycloalkenyl groups containing one double bond include a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, and a cyclooctenyl group.
[0080] The term "alkyl" as used herein refers to a straight or branched chain fully saturated hydrocarbon group, and examples of alkyl include methyl (Me), ethyl (Et), propyl (e.g., n-propyl and isopropyl groups), butyl (e.g., n-butyl, isobutyl, s-butyl, t-butyl), pentyl (e.g., n-pentyl, isopentyl group, neopentyl group), etc.
[0081] The term “haloalkyl” as used herein refers to alkyl substituted with one or more halogens, including both monosubstituted (e.g., -CH2F) and polysubstituted (e.g., -CF3).
[0082] Examples of compounds represented by the chemical formula 1 according to the present invention include the following compounds:
[0083] <1> N-(6-(1H-Benzo[d][1,2,3]triazol-1-yl)pyridin-2-yl)-5-(4-cyclopropyl-1H-imidazol-1-yl)-2-fluoro-4-methylbenzamide;
[0084] <2> 5-(4-Cyclopropyl-1H-imidazol-1-yl)-N-(6-(5,6-dihydrocyclopenta[d][1,2,3]triazol-1(4H)-yl)pyridin-2-yl)-2-fluoro-4-methylbenzamide;
[0085] <3> 5-(4-Cyclopropyl-1H-imidazol-1-yl)-2-fluoro-4-methyl-N-(6-(4,5,6,7-tetrahydro-1H-benzo[d][1,2,3]triazol-1-yl)pyridin-2-yl)methylbenzamide;
[0086] <4> 5-(4-cyclopropyl-1H-imidazol-1-yl)-2-fluoro-4-methyl-N-(6-(5,6,7,8-tetrahydrocyclohepta[d][1,2,3]triazol-1(4H)-yl)pyridin-2-yl)benzamide; and
[0087] <5> 5-(4-Cyclopropyl-1H-imidazol-1-yl)-2-fluoro-N-(6-(4,5,6,7,8,9-hexahydro-1H-cycloocta[d][1,2,3]triazol-1-yl)pyridin-2-yl)-4-methylbenzamide.
[0088]
[0089] One aspect of the present invention provides a method for producing a compound represented by Chemical Formula 1, comprising the step of producing a compound represented by Chemical Formula 1 by reacting a compound represented by Chemical Formula 2 with a compound represented by Chemical Formula 3, as shown in the following reaction scheme 1:
[0090] [Reaction Formula 1]
[0091]
[0092] In the above reaction formula 1 , R1, R2, and R3 are as defined in the above chemical formula 1.
[0093] The above reaction can be carried out under organic solvent conditions such as DMF (dimethylformamide) and NMP (N-methyl-2-pyrrolidone), and at this time, a catalyst material such as DMAP (4-dimethylaminopyridine) can be used.
[0094] In the above reaction, coupling agents such as HATU (hexafluorophosphate azabenzotriazole tetramethyl uronium) and T3P (propanephosphonic anhydride) can be used.
[0095] The above reaction can be carried out at 0°C to 50°C. For example, the above reaction can be carried out at 0°C to 40°C, 0°C to 30°C, 10°C to 50°C, 10°C to 40°C, 10°C to 30°C, 20°C to 50°C, 20°C to 40°C, or 20°C to 30°C.
[0096] The reaction can be carried out for 0.1 to 48 hours. For example, the reaction can be carried out for 0.1 to 36 hours, 0.1 to 24 hours, 0.5 to 48 hours, 0.5 to 36 hours, 0.5 to 24 hours, 1 to 48 hours, 1 to 36 hours, 1 to 24 hours, 2 to 48 hours, 2 to 36 hours, 2 to 24 hours, 3 to 48 hours, 3 to 36 hours, 3 to 24 hours, 4 to 48 hours, 4 to 36 hours, 4 to 24 hours, 6 to 48 hours, 6 to 36 hours, or 6 to 24 hours.
[0097]
[0098] The compound represented by the above chemical formula 1 of the present invention can be used in the form of a pharmaceutically acceptable salt, and as a salt, an acid addition salt formed by a pharmaceutically acceptable free acid is useful. The acid addition salt is obtained from inorganic acids such as hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, nitrous acid, phosphorous acid, etc.; non-toxic organic acids such as aliphatic mono- and dicarboxylates, phenyl-substituted alkanoates, hydroxyalkanoates and alkanedioates, aromatic acids, aliphatic and aromatic sulfonic acids, etc.; organic acids such as trifluoroacetic acid, acetate, benzoic acid, citric acid, lactic acid, maleic acid, gluconic acid, methanesulfonic acid, 4-toluenesulfonic acid, tartaric acid, fumaric acid, etc. These pharmaceutically non-toxic salts include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogen phosphate, dihydrogen phosphate, metaphosphate, pyrophosphate chloride, bromide, iodide, fluoride, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caprate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-1,4-dioate, hexane-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, Includes phthalate, terephthalate, benzenesulfonate, toluenesulfonate, chlorobenzenesulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, β-hydroxybutyrate, glycolate, malate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, mandelate, etc.
[0099] The acid addition salt according to the present invention can be prepared by a conventional method, for example, by dissolving the derivative of chemical formula 1 in an organic solvent such as methanol, ethanol, acetone, methylene chloride, acetonitrile, etc., adding an organic acid or inorganic acid, filtering and drying the resulting precipitate, or by distilling the solvent and an excess acid under reduced pressure, drying, and crystallizing in the presence of an organic solvent.
[0100] Additionally, pharmaceutically acceptable metal salts can be prepared using bases. Alkali metal or alkaline earth metal salts can be obtained, for example, by dissolving a compound in an excess of alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering the undissolved compound salt, and evaporating and drying the filtrate. Among the metal salts, sodium, potassium, or calcium salts are pharmaceutically suitable. Furthermore, the corresponding salts can be obtained by reacting an alkali metal or alkaline earth metal salt with a suitable anion salt (e.g., silver nitrate).
[0101] Furthermore, the present invention includes not only the compound represented by the above chemical formula 1 and its pharmaceutically acceptable salts, but also solvates, stereoisomers, hydrates, etc. that can be prepared therefrom.
[0102] The term "hydrate" as used herein refers to a compound of the present invention or a salt thereof containing a stoichiometric or non-stoichiometric amount of water bound by non-covalent intermolecular forces. The hydrate of the compound represented by the above chemical formula 1 of the present invention may contain a stoichiometric or non-stoichiometric amount of water bound by non-covalent intermolecular forces. The hydrate may contain at least 1 equivalent, preferably, 1 to 5 equivalents of water. Such a hydrate may be prepared by crystallizing the compound represented by the above chemical formula 1 of the present invention, a stereoisomer thereof, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof from water or a solvent containing water.
[0103] As used herein, the term "solvate" refers to a compound of the present invention or a salt thereof that contains a stoichiometric or non-stoichiometric amount of a solvent bound by non-covalent intermolecular forces. Preferred solvents include those that are volatile, non-toxic, and / or suitable for human administration.
[0104] The term "isomer" as used herein refers to a compound of the present invention or a salt thereof that has the same chemical formula or molecular formula but is structurally or sterically different. Such isomers include structural isomers including tautomers, and stereoisomers, and stereoisomers include optical isomers (enatiomers) and diastereomers that appear by having one or more asymmetric carbon centers, as well as geometric isomers (trans, cis). All of these isomers and mixtures thereof are also included in the scope of the present invention.
[0105] Additionally, the compound, a stereoisomer thereof, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof can inhibit ASK1.
[0106] Additionally, the compound, its stereoisomer, its solvate, its hydrate or its pharmaceutically acceptable salt can inhibit neuronal cell death.
[0107] One aspect of the present invention provides a pharmaceutical composition for preventing or treating an ASK1-related disease, comprising a compound represented by the above chemical formula 1, a stereoisomer thereof, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof as an active ingredient.
[0108] The pharmaceutical composition may further include a pharmaceutically acceptable carrier in addition to the above-mentioned active ingredient.
[0109] The above ASK1-related diseases include neurodegenerative diseases, cardiovascular diseases, autoimmune diseases, and liver diseases.
[0110] The above neurodegenerative diseases include Alzheimer's disease, hippocampal sclerosis, frontotemporal dementia (FTD), frontotemporal lobar degeneration (FTLD), Huntington's disease, corticobasal degeneration, amyotrophic lateral sclerosis, spinal muscular atrophy, motor neuron disease, inclusion body myositis, Parkinson's disease, dementia with Lewy bodies, Lewy body disease, multiple system atrophy, progressive supranuclear palsy, Pick's disease, prion disease, traumatic brain injury, ischemic and hemorrhagic stroke, cerebral ischemia, hypoxia, and glutamate neurotoxicity.
[0111] The above cardiovascular diseases include heart failure, ischemia, recurrent ischemia, myocardial infarction, arrhythmia, acute coronary syndrome, diabetes, atherosclerosis and intermittent claudication.
[0112] The above autoimmune diseases include rheumatoid arthritis, fibromyalgia, systemic lupus erythematosus, multiple sclerosis, diabetes, systemic sclerosis, Graves' disease, Guillain-Barré syndrome, myasthenia gravis, psoriasis, Crohn's disease, ulcerative colitis, optic neuritis, and Sjogren's syndrome.
[0113] The above liver diseases include non-alcoholic fatty liver disease (NASH), alcoholic fatty liver disease, liver fibrosis, liver cancer, hepatotoxicity, cholestasis, cirrhosis, liver ischemia, liver abscess, hepatic coma, and liver atrophy.
[0114] The compound represented by the above chemical formula 1 or a pharmaceutically acceptable salt thereof can be administered in various oral and parenteral dosage forms during clinical administration. When formulated, it is prepared using diluents or excipients such as commonly used fillers, bulking agents, binders, wetting agents, disintegrants, and surfactants. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations are prepared by mixing one or more compounds with at least one excipient, such as starch, calcium carbonate, sucrose or lactose, gelatin, etc. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral administration include suspensions, solutions, emulsions, and syrups. In addition to commonly used simple diluents such as water and liquid paraffin, they may contain various excipients such as wetting agents, sweeteners, fragrances, and preservatives. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, and emulsions. Non-aqueous solvents and suspensions can include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate.
[0115] A pharmaceutical composition containing the compound represented by the above chemical formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient can be administered parenterally, and parenteral administration is by subcutaneous injection, intravenous injection, intramuscular injection, or intrathoracic injection.
[0116] At this time, in order to formulate a dosage form for parenteral administration, the compound represented by the above chemical formula 1 or a pharmaceutically acceptable salt thereof is mixed with a stabilizer or buffer in water to prepare a solution or suspension, which can be prepared in an ampoule or vial unit dosage form. The composition may be sterilized and / or contain auxiliary agents such as preservatives, stabilizers, wetting agents or emulsifying promoters, salts for osmotic pressure control and / or buffers, and other therapeutically useful substances, and may be formulated according to conventional mixing, granulation or coating methods.
[0117] Oral dosage forms include, for example, tablets, pills, hard / soft capsules, solutions, suspensions, emulsions, syrups, granules, elixirs, and troches, which contain, in addition to the active ingredient, diluents (e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, and / or glycine), lubricants (e.g., silica, talc, stearic acid and its magnesium or calcium salts, and / or polyethylene glycol). Tablets may contain binders such as magnesium aluminum silicate, starch paste, gelatin, methylcellulose, sodium carboxymethylcellulose, and / or polyvinylpyrrolidine, and, if desired, disintegrating agents or effervescent mixtures such as starch, agar, alginic acid or its sodium salt, and / or absorbents, coloring agents, flavoring agents, and sweetening agents.
[0118] The compound represented by the above chemical formula 1 of the present invention, a stereoisomer thereof, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, is administered in a “pharmaceutically effective amount.” As used herein, the term “pharmaceutically effective amount” means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment or improvement, and the effective dosage level can be determined according to factors including the subject type and severity, age, sex, activity of the drug, sensitivity to the drug, time of administration, route of administration and excretion rate, treatment period, concurrently used drugs, and other factors well known in the medical field. For example, an effective amount of 0.001 mg / kg to 1000 mg / kg, 0.01 mg / kg to 100 mg / kg, or 0.1 to 20 mg / kg, or 0.1 to 500 mg / kg is included. The amount of the compound or pharmaceutical composition of the present invention can be selected and implemented within an appropriate range by a person skilled in the art.
[0119]
[0120] One aspect of the present invention provides a health functional food for preventing or improving ASK1-related diseases, which contains a compound represented by the above chemical formula 1, a stereoisomer thereof, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof as an active ingredient.
[0121] The compound represented by chemical formula 1 according to the present invention exhibits high ASK1 inhibitory activity, and thus can be manufactured as a pharmaceutical composition for a health functional food composition for preventing or improving ASK1-related diseases, or can be added to health functional food supplements such as foods and beverages.
[0122] The compound represented by the above chemical formula 1 according to the present invention can be added directly to food or used together with other foods or food ingredients, and can be used appropriately according to a conventional method. The amount of the active ingredient mixed can be appropriately determined depending on its purpose of use (prevention or improvement). Generally, the amount of the compound in a health food can be added in an amount of 0.1 to 90 parts by weight based on the total food weight. However, in the case of long-term intake for the purpose of health and hygiene or health control, the amount can be below the above range, and since there is no problem in terms of safety, the active ingredient can also be used in an amount exceeding the above range.
[0123]
[0124] One aspect of the present invention provides a method for preventing or treating an ASK1-related disease, comprising administering to a subject in need thereof a pharmaceutical composition containing a compound represented by the above chemical formula 1, a stereoisomer thereof, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof as an active ingredient.
[0125] The above administration may be oral or parenteral. In case of oral administration, the active ingredient may be administered in an amount of 0.01 to 1000 mg, more specifically 0.1 to 300 mg per kg of body weight per day, and in case of parenteral administration, the active ingredient may be administered in an amount of 0.01 to 100 mg, more specifically 0.1 to 50 mg per kg of body weight per day, and may be administered in one or more divided doses. The dosage for a specific individual or patient should be determined in light of various related factors such as the patient's weight, age, sex, health condition, diet, administration time, administration method, and severity of the disease, and may be appropriately increased or decreased by a specialist.
[0126] As used herein, the term "subject" means a subject in need of treatment for a disease, and more specifically, a mammal such as a human or non-human primate, mouse, dog, cat, horse, and cow.
[0127] One aspect of the present invention provides the use of a compound represented by the above chemical formula 1, a stereoisomer thereof, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof for use in the prevention or treatment of an ASK1-related disease.
[0128] One aspect of the present invention provides a use of a compound represented by the above chemical formula 1, a stereoisomer thereof, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof for preparing a medicament for preventing or treating an ASK1-related disease.
[0129]
[0130] Hereinafter, the present invention will be described in detail through examples and experimental examples.
[0131] However, the following examples and experimental examples are only illustrative of the present invention, and the content of the present invention is not limited to the following examples and experimental examples.
[0132] Manufacturing Example 1. 6-(1H-Benzo[d][1,2,3]triazol-1-yl)pyridin-2-amine (Intermediate 1)
[0133]
[0134] According to the above reaction formula, intermediate 1 was obtained.
[0135] A mixture of 6-fluoropyridin-2-amine (200 mg, 1.78 mmol), benzotriazole (255 mg, 2.14 mmol), and K2CO3 (740 mg, 5.34 mmol) in DMSO (6 mL) was heated at 180°C for 12 h. After cooling to room temperature, 1 M Na2CO3 solution was added. The resulting solid was filtered and dried under reduced pressure to give 6-(1H-benzo[d][1,2,3]triazol-1-yl)pyridin-2-amine (intermediate 1, 230 mg, 61%). 1 H NMR (500 MHz, Chloroform-d) δ 8.45 (d,J= 8.4 Hz, 1H), 8.11 (d,J= 8.3 Hz, 1H), 7.72 (t,J= 8.0 Hz, 1H), 7.59 (t,J= 7.7 Hz, 1H), 7.48 (d,J= 7.7 Hz, 1H), 7.44 (t,J= 7.7 Hz, 1H), 6.68 (d,J= 8.2 Hz, 1H); LCMS: 212.4 [M+H + ].
[0136] Manufacturing Example 2. 6-(5,6-dihydrocyclopenta[d][1,2,3]triazol-1(4H)-yl)pyridin-2-amine (intermediate 2)
[0137] Intermediate 2 was obtained according to the following reaction formula.
[0138]
[0139] Step 1: 1-Azido-4-nitrobenzene
[0140] 4-Nitroaniline (1.00 g, 7.24 mmol) was dissolved in anhydrous acetonitrile (20 mL) and cooled to 0°C in an ice bath. To the stirred solution, tert-butyl nitrite (1.03 mL, 8.69 mmol) was added, and the resulting mixture was stirred for 20 min. Azidotrimethylsilane (1.44 mL, 10.86 mmol) was then added dropwise over 10 min, and the final brown solution was stirred at room temperature for 12 h. The solvent was removed under reduced pressure. The residue was purified by flash column chromatography using silica gel (hexane / ethyl acetate 100 / 0->80 / 20) to give 1-azido-4-nitrobenzene (1.16 g, 97%).
[0141] 1 H NMR (400 MHz, Methanol-d4) δ 8.30 - 8.25 (m, 2H), 7.30 - 7.25 (m, 2H); LCMS: 165.5 [M+H + ].
[0142] Step 2: 1,4,5,6-Tetrahydrocyclopenta[d][1,2,3]triazole
[0143] Cyclopentanone (1.08 mL, 12.2 mmol), NH4OAc (4.69 g, 60.9 mmol), and 1-azido-4-nitrobenzene were added to a screw-capped reaction tube equipped with a magnetic stir bar. The resulting mixture was dissolved in DMF (20 mL) and stirred at 80°C for 12 h. Upon completion, DMF was removed under reduced pressure, and the residue was purified by flash column chromatography on silica gel (DCM 100%, then hexane / ethyl acetate 100 / 0->50 / 50) to give 1,4,5,6-tetrahydrocyclopenta[d][1,2,3]triazole (164 mg, 61%).
[0144] 1H NMR (300 MHz, Chloroform-d) δ 10.03 (s, 1H), 2.88 - 2.78 (m, 4H), 2.66 - 2.54 (m, 2H).
[0145] Step 3: 6-(5,6-dihydrocyclopenta[d][1,2,3]triazol-1(4H)-yl)pyridin-2-amine
[0146] A mixture of 6-fluoropyridin-2-amine (940 mg, 8.32 mmol), 1,4,5,6-tetrahydrocyclopenta[d][1,2,3]triazole (1.00 g, 9.16 mmol), and K2CO3 (3.44 g, 25.0 mmol) in DMSO (20 mL) was heated at 160°C for 12 h. After cooling to room temperature, the mixture was diluted with water and extracted twice with acetyl acetate. The combined organic layers were washed with brine, dried over MgSO4, filtered, and concentrated. The residue was purified by flash column chromatography using silica gel (hexane / ethyl acetate 100 / 0->60 / 40) to obtain 6-(5,6-dihydrocyclopenta[d][1,2,3]triazol-1(4H)-yl)pyridin-2-amine (intermediate 2, 700 mg, 42%).
[0147] 1 H NMR (300 MHz, Chloroform-d) δ 7.59 (t,J= 7.9 Hz, 1H), 7.41 (dd,J= 7.8, 0.7 Hz, 1H), 6.45 (dd,J= 8.0, 0.7 Hz, 1H), 3.18 - 3.05 (m, 2H), 2.88 - 2.76 (m, 2H), 2.73 - 2.59 (m, 2H); LCMS: 202.6 [M+H + ].
[0148] Manufacturing Example 3. 6-(4,5,6,7-tetrahydro-1H-benzo[d][1,2,3]triazol-1-yl)pyridin-2-amine (Intermediate 3)
[0149]
[0150] The same method as in Manufacturing Example 2 was performed to obtain 6-(4,5,6,7-tetrahydro-1H-benzo[d][1,2,3]triazol-1-yl)pyridin-2-amine (intermediate 3, 39%).
[0151] 1 H NMR (300 MHz, Chloroform-d) δ 7.60 (t,J= 7.9 Hz, 1H), 7.35 (dd,J= 7.8, 0.7 Hz, 1H), 6.48 (dd,J= 8.2, 0.7 Hz, 1H), 3.13 - 3.03 (m, 2H), 2.86 - 2.75 (m, 2H), 1.90 - 1.78 (m, 4H); LCMS: 216.6 [M+H + ].
[0152] Manufacturing Example 4. 6-(5,6,7,8-tetrahydrocyclohepta[d][1,2,3]triazol-1(4H)-yl)pyridin-2-amine (intermediate 4)
[0153]
[0154] The same method as in Manufacturing Example 2 was performed to obtain 6-(5,6,7,8-tetrahydrocyclohepta[d][1,2,3]triazol-1(4H)-yl)pyridin-2-amine (intermediate 4, 22%).
[0155] 1 H NMR (400 MHz, Methanol-d4) δ 7.65 (t,J= 7.9 Hz, 1H), 6.84 (d,J= 7.5 Hz, 1H), 6.67 (d,J= 8.3 Hz, 1H), 3.07 - 2.97 (m, 2H), 2.95 - 2.86 (m, 2H), 1.96 - 1.85 (m, 2H), 1.81 - 1.69 (m, 4H); LCMS: 230.6 [M+H + ].
[0156] Manufacturing Example 5. 6-(4,5,6,7,8,9-hexahydro-1H-cycloocta[d][1,2,3]triazol-1-yl)pyridin-2-amine (intermediate 5)
[0157]
[0158] The same method as in Manufacturing Example 2 was performed to obtain 6-(4,5,6,7,8,9-hexahydro-1H-cycloocta[d][1,2,3]triazol-1-yl)pyridin-2-amine (intermediate 5.23%).
[0159] 1 H NMR (500 MHz, Chloroform-d) δ 7.65 (t,J= 7.9 Hz, 1H), 7.20 - 7.10 (m, 1H), 6.74 - 6.63 (m, 1H), 3.17 - 3.09 (m, 2H), 3.06 - 2.99 (m, 2H), 1.94 - 1.87 (m, 2H), 1.85 - 1.76 (m, 2H), 1.57 - 1.45 (m, 4H); LCMS: 244.6 [M+H + ].
[0160] Manufacturing Example 6. 6-(4,5,6,7-tetrahydro-1H-benzo[d][1,2,3]triazol-1-yl)pyridin-2-amine (alternative method for preparing intermediate 3)
[0161] The above intermediate 3 can also be prepared according to the following reaction formula.
[0162]
[0163] Step 1. 2,2-dimethoxycyclohexan-1-one
[0164] To a solution of trimethylsilyl chloride (7.0 ml, 58.9 mmol) in methanol (500 ml) was slowly added a solution of cyclohexane-1,2-dione (6.0 g, 53.5 mmol) in methanol (50 ml), and the resulting mixture was stirred at room temperature for 16 h. The reaction mixture was poured into water and extracted with diethyl ether. The organic layer was washed with a saturated ammonium carbonate solution, water, and brine. After drying over MgSO4, the solvent was removed under reduced pressure to obtain 2,2-dimethoxycyclohexan-1-one (quantitative yield).
[0165] 1H NMR (400 MHz, DMSO-d6) δ 3.14 (s, 6H), 2.39 (t, J = 6.6 Hz, 2H), 1.85 (t, J = 6.0 Hz, 2H), 1.77 - 1.68 (m, 2H), 1.68 - 1.60 (m, 2H).
[0166] Step 2. 6-(4,5,6,7-tetrahydro-1H-benzo[d][1,2,3]triazol-1-yl)pyridin-2-amine
[0167] To a solution of 2,2-dimethoxycyclohexan-1-one (5.6 g, 35.4 mmol) in isopropanol (100 ml) was added 4-methylbenzenesulfonohydrazide (6.0 g, 32.2 mmol) and stirred at room temperature for 30 min (at this stage, consumption of 4-methylbenzenesulfonohydrazide was observed). To the mixture were added pyridine-2,6-diamine (3.86 g, 35.4 mmol) and triethylamine (4.9 ml, 35.4 mmol). After 3 h at 140°C and cooling to room temperature, the reaction mixture was partitioned between dichloromethane and water, and the organic layer was then separated. The aqueous layer was extracted twice more with dichloromethane, and the combined organic extracts were washed with brine, dried over MgSO4, and concentrated. The product was purified using flash column chromatography using silica gel (hexane / ethyl acetate 100 / 0->50 / 50) to obtain 6-(4,5,6,7-tetrahydro-1H-benzo[d][1,2,3]triazol-1-yl)pyridin-2-amine (intermediate 3, 3.0 g, 43%).
[0168] 1 H NMR (400 MHz, DMSO-d6) δ 7.59 (t,J= 7.9 Hz, 1 H), 6.99 (d,J= 7.5 Hz, 1 H), 6.48 (d,J= 8.2 Hz, 1 H), 6.33 (s, 2 H), 3.03 (d,J= 3.2 Hz, 2 H), 2.68 (s, 2 H), 1.84 - 1.72 (m, 4 H); LCMS [M+H]; 216.27.
[0169]
[0170] Example 1. N-(6-(1H-Benzo[d][1,2,3]triazol-1-yl)pyridin-2-yl)-5-(4-cyclopropyl-1H-imidazol-1-yl)-2-fluoro-4-methylbenzamide
[0171]
[0172] Compound Example 1 was prepared according to the above reaction formula.
[0173] To a stirred solution of 6-(1H-benzo[d][1,2,3]triazol-1-yl)pyridin-2-amine (intermediate 1, 70 mg, 0.33 mmol), DMAP (400 mg, 3.30 mmol), and 5-(4-cyclopropyl-1H-imidazol-1-yl)-2-fluoro-4-methylbenzoic acid (130 mg, 0.50 mmol) [purchased from AA blocks (5 g), Labnetwork (10 g), Chemscene; reference: WO 2013 / 112741] in DMF (3 mL) was added HATU (1.25 g, 3.30 mmol) at room temperature. The resulting mixture was stirred at room temperature for 12 h and then diluted with ethyl acetate and saturated aqueous NaHCO3 solution. The separated organic layer was washed with brine, dried over anhydrous MgSO4, and filtered. The organic filtrate was evaporated under reduced pressure. The obtained material was purified by flash column chromatography using silica gel (ethyl acetate / methanol 100 / 0->90 / 10) and C18-reverse phase HPLC (using 0.1% TFA in H2O and 0.1% TFA in ACN as buffer solvents) to give N-(6-(1H-benzo[d][1,2,3]triazol-1-yl)pyridin-2-yl)-5-(4-cyclopropyl-1H-imidazol-1-yl)-2-fluoro-4-methylbenzamide (1, 35 mg, 23%).
[0174] 1H NMR (300 MHz, Methanol-d4) δ 9.07 (d,J= 1.7 Hz, 1H), 8.84 (dd,J= 8.4, 1.0 Hz, 1H), 8.29 (dd,J= 7.6, 1.3 Hz, 1H), 8.18 - 8.04 (m, 3H), 7.97 (d,J= 6.4 Hz, 1H), 7.70 - 7.63 (m, 1H), 7.60 - 7.56 (m, 1H), 7.56 - 7.50 (m, 1H), 7.47 (d,J= 10.8 Hz, 1H), 2.34 (s, 3H), 2.12 - 2.01 (m, 1H), 1.19 - 1.10 (m, 2H), 0.91 (dt,J= 7.0, 4.7 Hz, 2H); LCMS: 454.6 [M+H + ].
[0175] Example 2. 5-(4-Cyclopropyl-1H-imidazol-1-yl)-N-(6-(5,6-dihydrocyclopenta[d][1,2,3]triazol-1(4H)-yl)pyridin-2-yl)-2-fluoro-4-methylbenzamide
[0176]
[0177] To a stirred solution of commercially available 5-(4-cyclopropyl-1H-imidazol-1-yl)-2-fluoro-4-methylbenzoic acid (0.38 g, 1.3 mmol) in NMP (3.0 ml) was added DMAP (0.36 g, 3.0 mmol), followed by slow addition of T3P (50% ethyl acetate) (1.27 ml, 2.0 mmol) at room temperature. The resulting mixture was stirred for 10 minutes, 6-(5,6-dihydrocyclopenta[d][1,2,3]triazol-1(4H)-yl)pyridin-2-amine (0.2 g, 1.0 mmol) was added, and the mixture was stirred for 12 hours. The reaction mixture was quenched with ice-cold water and basified (pH 7-8) with saturated aqueous NaHCO3 solution. The obtained solid was filtered, washed with water, and dried. The solid was permeated with ethyl acetate to obtain the desired 5-(4-cyclopropyl-1H-imidazol-1-yl)-N-(6-(5,6-dihydrocyclopenta[d][1,2,3]triazol-1(4H)-yl)pyridin-2-yl)-2-fluoro-4-methylbenzamide compound as a pure white solid (0.3 g, 68%).
[0178] 1 H NMR (400 MHz, DMSO) δ 10.96 (s, 1 H), 8.19 - 8.08 (m, 2 H), 7.78 (dd,J= 7.6, 1.0 Hz, 1 H), 7.69 (d,J= 1.4 Hz, 1 H), 7.63 (d,J= 6.6 Hz, 1 H), 7.48 (d,J= 10.8 Hz, 1 H), 7.18 (d,J= 1.4 Hz, 1 H), 3.14 (t,J= 7.1 Hz, 2 H), 2.78 - 2.70 (m, 2 H), 2.67 - 2.57 (m, 2 H), 2.25 (s, 3) H), 1.85 (td,J=8.3, 4.1 Hz, 1 H), 0.83 - 0.77 (m, 2 H), 0.73 - 0.67 (m, 2 H): LCMS; [M+H] + 444.6.
[0179] Example 3. 5-(4-Cyclopropyl-1H-imidazol-1-yl)-2-fluoro-4-methyl-N-(6-(4,5,6,7-tetrahydro-1H-benzo[d][1,2,3]triazol-1-yl)pyridin-2-yl)methylbenzamide
[0180]
[0181] To a stirred solution of commercially available 5-(4-cyclopropyl-1H-imidazol-1-yl)-2-fluoro-4-methylbenzoic acid (3.93 g, 15.1 mmol) in NMP (30 ml) was added DMAP (4.25 g, 34.8 mmol), followed by slow addition of T3P (50% ethyl acetate) (14.7 g, 23.2 mmol) at room temperature. The resulting mixture was stirred for 10 minutes, 6-(4,5,6,7-tetrahydro-1H-benzo[d][1,2,3]triazol-1-yl)pyridin-2-amine (2.5 g, 11.6 mmol) was added, and the mixture was stirred for 12 hours. The reaction mixture was quenched with ice-cold water and basified (pH 7-8) with saturated aqueous NaHCO3 solution. The obtained solid was filtered, washed with water, and dried. The solid was permeated with methanol to obtain the desired 5-(4-cyclopropyl-1H-imidazol-1-yl)-2-fluoro-4-methyl-N-(6-(4,5,6,7-tetrahydro-1H-benzo[d][1,2,3]triazol-1-yl)pyridin-2-yl)benzamide compound as a white solid (5.0 g, 94%).
[0182] 1H NMR (400 MHz, DMSO) δ 11.03 (s, 1 H), 8.19 (dd,J= 8.3, 0.9 Hz, 1 H), 8.12 (t,J= 8.0 Hz, 1 H), 7.75 (dd,J= 7.8, 0.8 Hz, 1 H), 7.70 (d,J= 1.5 Hz, 1 H), 7.63 (d,J= 6.5 Hz, 1 H), 7.48 (d,J= 10.7 Hz, 1 H), 7.18 (d,J= 1.4 Hz, 1 H), 3.11 (d,J= 5.3 Hz, 2 H), 2.70 (d,J= 4.6 Hz, 2 H), 2.25 (s, 3 H), 1.90 - 1.82 (m, 1 H), 1.81 - 1.75 (m, 4 H), 0.84 - 0.78 (m, 2 H), 0.73 - 0.67 (m, 2 H). LCMS [M+H]; 458.57.
[0183] Example 4. 5-(4-Cyclopropyl-1H-imidazol-1-yl)-2-fluoro-4-methyl-N-(6-(5,6,7,8-tetrahydrocyclohepta[d][1,2,3]triazol-1(4H)-yl)pyridin-2-yl)benzamide
[0184] The same method as in Example 1 was followed except that Intermediate 4 was used instead of Intermediate 1 to obtain 5-(4-cyclopropyl-1H-imidazol-1-yl)-2-fluoro-4-methyl-N-(6-(5,6,7,8-tetrahydrocyclohepta[d][1,2,3]triazol-1(4H)-yl)pyridin-2-yl)benzamide (13%).
[0185] 1H NMR (400 MHz, Methanol-d4) δ 9.03 (d,J= 1.6 Hz, 1H), 8.39 (d,J= 8.3 Hz, 1H), 8.11 (t,J= 8.1 Hz, 1H), 7.94 (d,J= 6.4 Hz, 1H), 7.60 (d,J= 7.8 Hz, 1H), 7.57 - 7.52 (m, 1H), 7.46 (d,J= 10.9 Hz, 1H), 3.18 - 3.12 (m, 2H), 2.94 - 2.89 (m, 2H), 2.32 (s, 3H), 2.08 - 2.01 (m, 1H), 1.96 - 1.88 (m, 2H), 1.82 - 1.73 (m, 4H), 1.16 - 1.10 (m, 2H), 0.92 - 0.87 (m, 2H); LCMS: 472.5 [M+H + ].
[0186] Example 5. 5-(4-Cyclopropyl-1H-imidazol-1-yl)-2-fluoro-N-(6-(4,5,6,7,8,9-hexahydro-1H-cycloocta[d][1,2,3]triazol-1-yl)pyridin-2-yl)-4-methylbenzamide
[0187] The same method as in Example 1 was performed to obtain 5-(4-cyclopropyl-1H-imidazol-1-yl)-2-fluoro-N-(6-(4,5,6,7,8,9-hexahydro-1H-cycloocta[d][1,2,3]triazol-1-yl)pyridin-2-yl)-4-methylbenzamide (4%).
[0188] 1H NMR (500 MHz, Methanol-d4) δ 9.10 (d,J= 1.7 Hz, 1H), 8.38 (d,J= 8.2 Hz, 1H), 8.11 (t,J= 8.1 Hz, 1H), 7.99 (d,J= 6.4 Hz, 1H), 7.70 (d,J= 7.8 Hz, 1H), 7.58 (d,J= 1.3 Hz, 1H), 7.48 (d,J= 11.0 Hz, 1H), 3.25 - 3.20 (m, 2H), 2.97 - 2.92 (m, 2H), 2.33 (s, 3H), 2.08 - 2.02 (m, 1H), 1.96 - 1.89 (m, 2H), 1.82 - 1.75 (m, 2H), 1.59 - 1.54 (m, 2H), 1.54 - 1.48 (m, 2H), 1.18 - 1.11 (m, 2H), 0.94 - 0.88 (m, 2H); LCMS: 486.5 [M+H + ].
[0189] The structural formulas of the compounds manufactured in Examples 1 to 5 are summarized and shown in Table 1 below.
[0190] [Table 1]
[0191]
[0192] Experimental Example 1. Confirmation of ASK1 inhibitory activity
[0193] In order to measure the ASK1 activity inhibitory ability of the compound represented by chemical formula 1 according to the present invention, the following experiment was performed.
[0194] Recombinant human ASK1 protein was added to the reaction solution (8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.33 mg / mL myelin basic protein, 10 mM Mg Acetate, and [gamma-33P]-ATP) to initiate the reaction, and after reacting for 40 minutes at room temperature, the reaction was terminated by adding 0.5% phosphoric acid. After that, 10 uL of the reaction solution was dropped onto a P30 dropper filter, washed 4 times in 0.425% phosphoric acid for 4 minutes each, dried in methanol, and measured for ASK1 activity by scintillation counting. The activity value from the group without the compound was set as 100%, and the degree of ASK2 inhibition by the compound was converted, and the ASK1 inhibitory activity of the example compounds is summarized in Table 2 below.
[0195] Example: Remaining kinase activity (%) at 0.5uMIC 50 (nM)114235223737734-925-198Comparative Example 1 (Selonsertib)0107
[0196] Looking at Table 2 above, it was confirmed that the compound represented by Chemical Formula 1 according to the present invention is a substance having ASK1 inhibitory activity. Therefore, the compound of the present invention can be usefully used as a composition for preventing or treating neurodegenerative brain diseases caused by ASK1.
[0197] Experimental Example 2. Evaluation of the cytoprotective effect in MPP+-induced human neural cells.
[0198] In order to evaluate the effect of the compound represented by chemical formula 1 according to the present invention on protecting dopaminergic neurons from damage, the following experiment was performed.
[0199] SH-SY5Y cells were purchased from ATCC and cultured in RPMI medium containing 10% FBS and 1% penicillin and streptomycin at 37°C under 5% CO2 conditions. MPP+ was purchased from Sigma Aldrich and cytotoxicity was induced by treatment with 5 mM. Cell viability was measured by measuring the absorbance at 540 nm 1-3 hours after treatment with CCK-8 reagent, and the results are shown in Table 3 below.
[0200] EC in Example SH-SY5Y 50 (nM)264323Comparative Example 1 (Selonsertib)89
[0201] As shown in Table 3 and Figure 1 above, the compounds of the present invention showed excellent cytoprotective effects in SH-SY5Y cells, and in particular, Examples 2 and 3 showed better EC than Comparative Example 1 (Selonsertib). 50 Showed the value.
[0202] Experimental Example 3. Cell Viability Evaluation
[0203] To evaluate cell viability upon compound treatment, BV2 cells were seeded at 2x10 per well in a 96-well plate. 4 After seeding one by one and culturing for one day, the cells were treated with compounds at concentrations of 0.1 μM, 0.3 μM, and 1 μM, respectively, and cultured for 72 h at 37°C in 5% CO2. Cell viability was quantified using the absorbance measured at a wavelength of 565 nm using a Hidex sense microplate reader (Hidex, Turku, Finland) after adding Cell Counting Kit-8 (CCK-8; LPS solution, Seoul, Korea) to the cultured cells.
[0204] As shown in Fig. 2, the example compound according to the present invention showed a cell viability rate similar to that of Comparative Example 1 (selonsertib).
[0205] Experimental Example 4. Evaluation of Anti-Inflammatory Efficacy
[0206] BV2 cells (2 x 10 per well) 4 Cells) were cultured in 96-well culture plates for 24 hours. After treatment with the example compounds at concentrations of 0.1 μM, 0.3 μM, and 1 μM for 1 hour, 100 pg / ml of LPS was added, and the cells were cultured for 24 hours. After culture, the conditioned medium (CM) was harvested and centrifuged at 2000 rpm. After centrifugation, the supernatant was separated, and TNF-α secreted from the cell culture medium in the supernatant was measured using the corresponding ELISA kit (LABISKOMA, Seoul, Korea).
[0207] As shown in Fig. 2, the compound of the present invention reduced the secretion of the inflammatory cytokine TNF-α induced by LPS to a level similar to that of selonsertib (Comparative Example 1). In particular, Example 3 was confirmed to have excellent anti-inflammatory efficacy by reducing TNF-α secretion at all concentrations compared to selonsertib.
[0208] Experimental Example 5. Evaluation of neuroprotective efficacy
[0209] 6-OHDA (6-hydroxydopamine hydrobromide) and MPP, substances that cause neurotoxicity + (1-methyl-4-phenylpyridinium) was purchased from Sigma-Aldrich (Saint Louis, MO, USA) and used as a 100 mM DMSO stock. PC12 cells were seeded in 96-well plates at a density of 1 × 10 per well. 4Cells were seeded individually and cultured for 1 day. Cells were pretreated with the respective concentrations of the example compounds for 1 hour. Afterwards, 40 μM 6-OHDA and 2 mM MPP+ were added, respectively, and cultured for 24 hours. Cell viability was then measured using the MTT assay (Invitrogen, MA, USA).
[0210] As shown in Tables 4 and 5, the compound of the present invention showed a superior cell survival rate than Comparative Example 1 (selonsertib), confirming that it has an excellent neuroprotective effect in the PC-12 cell line.
[0211] Group control 6-OHDA Comparative Example 1 (μM) (Selonsertib) Example 3 (μM) Example 2 (μM) (40 μM) 0.10.31 0.10.31 0.10.31 AVE 10 0 8 1.5 187.9 189.1884.09 89.95 9 1.9 8 9 2.77 8 8.8 5 9 1.4 9 9 6.78 STDEV 0.9 1.8 3 0.9 2 1.1 2 2 3 1 1.3 7 1.0 2 2 8 5 2.3 3 1.4 2 1.28
[0212] GroupControlMPPComparative Example 1 (μM)(Selonsertib)Example 3 (μM)Example 2 (μM)(2 mM)0.10.310.10.310.10.31AVE10080.0983.5881.3181.3187.487.5689.8983.8791.7192.44STDEV1.742.372.391.941.403.721.021.552.980.232.07
[0213] Experimental Example 6. Evaluation of TG synthesis inhibition effect
[0214] Triglyceride (TG) measurement was performed on human liver cancer cells, HepG2 cells, in a 96-well plate at 2x10 per well. 4Cells were seeded and cultured for 24 hours. The cultured cells were pretreated with the example compounds at various concentrations for 2 hours, and then 1 mM of free fatty acid (FFA) consisting of a 1:2 ratio of palmitic acid (PA, sigma, #P9767) and oleic acid (OA, sigma, #O7501) was added, and the cells were cultured for 48 hours. After culture, the supernatant was separated and the absorbance was measured at 570 nm using a Triglyceride Quantification Kit (sigma, #MAK266).
[0215] As shown in Table 6 below, the anti-NASH (non-alcoholic steatohepatitis) efficacy was verified by inhibition of TG synthesis. As a result of the experiment, the compound of Example 3 showed a better TG synthesis inhibition effect as the treatment concentration increased.
[0216] HepG2FFA 1mM + Example 3 (0 μM)FFA 1mM + Example 3 (0.3 μM)FFA 1mM + Example 3 (1 μM)Cell Viability (% of HepG2 control) 100 93.97 99.06 93.10 TG Level (% of HepG2 control) 100 125.86 117.38 * 106.59 *
[0217] Experimental Example 7. Evaluation of MDR-MDCK Cell Membrane Permeability
[0218] To measure the permeability through the MDR-MDCK cell monolayer, MDCK-MDR1 cells (5Х10 5 cells / mL) were cultured in a 24-transwell plate (Corning, NY, USA) for 4 days. The medium was replaced with fresh medium every other day, and the transepithelial electrical resistance (TEER) value was measured using a Millicell® ERS-2 Volohmmeter (Merck KGaA, Darmstadt, Germany), and the value was 300 Ohm.cm 2 After confirming the above, a cell membrane permeability test was performed.
[0219] The apical and basolateral chambers were washed twice each with DPBS buffer and Hanks' Balanced Salt Solution (HBSS) containing 10 mM Hydroxyethyl piperazine Ethane Sulfonic acid (HEPES). In the final washing step, HBSS was filled and the chambers were kept at 37°C for 30 minutes. After 30 minutes, the test substance was instilled into each chamber and kept at 37°C for 2 hours. The culture medium of the transferred layer was collected at 30-minute intervals, and the collected amount was replenished with fresh HBSS.
[0220] The apparent permeability coefficient (Papp, cm / sec) was calculated using the following formula:
[0221] [Mathematical Formula 1]
[0222] Papp =dQ / dt Х 1 / A Х 1 / C_0
[0223] * Papp: Apparent permeability
[0224] * dQ / dt: Permeability of the drug
[0225] * A: Area of the filter membrane on which cells are laid
[0226] * C_0: Initial drug concentration
[0227] Additionally, the efflux ratio was calculated as follows.
[0228] [Equation 2]
[0229] Efflux ratio (ER) = (Papp (Basolateral to Apical)) / (Papp (Apical to Basolateral))
[0230] Example Papp (X 10 -6cm / sec)Efflux ratioA to BB to A293.2 ± 11.299.1 ± 16.81.06367.3 ± 12.874.8 ± 12.31.13457.3 ± 4.2387.4 ± 3.391.53Comparative example 1 (Selonsertib)3.82 ± 0.66102 ± 2.9727
[0231] As shown in Table 7, Comparative Example 1 compound (Selonsertib) showed an efflux coefficient of 27 due to a large difference in the apparent coefficients in the absorption and efflux directions, confirming that it is a substrate for an efflux transporter, whereas the example compounds according to the present invention showed very high apparent multiple values and an efflux ratio close to 1 in both the absorption and efflux directions, confirming that it easily permeates the cell membrane and is not a substrate for an efflux transporter.
[0232] Experimental Example 8. Distribution in the mouse brain
[0233] The blood-brain barrier permeability in ICR mice was determined by oral administration of 10 mg / kg of the test substance. Male C57BL / 6 mice were fasted for 15 h prior to administration. The test substance was administered at a dose of 10 mg / kg and a volume of 5 mL / kg. The administration vehicle composition was prepared by volume ratio of N-Methyl-2-pyrrolidone (NMP), polyethylene glycol 400 (PEG 400), and distilled water (DW) at a ratio of 10:40:50 (%). After administration, mice were sacrificed by carbon dioxide inhalation at time points corresponding to 1, 4, and 8 h, and blood and brain tissue samples were collected. Whole blood was collected from the iliac vein, and brain samples were collected after systemic perfusion with saline to remove as much blood as possible.
[0234] The distribution ratio in mouse plasma and brain was calculated by calculating the AUC after quantifying the concentration in each tissue.
[0235] [Equation 3]
[0236] Kp = (Total brain AUC) / (Total plasma AUC)
[0237] Compound AUC inf (ug*h.ml or ug*hg)Kp plasma brain Example 3320 ± 74.8 6.61 ± 1.75 0.021 Comparative Example 1 (Selonsertib) 69.9 ± 3.48 0.26 ± 0.03 0.004
[0238] As shown in Table 8, Example 3 according to the present invention had relatively higher concentrations and Kp values in plasma and brain than Comparative Example 1 (Selonsertib), confirming that it has excellent pharmacodynamic properties for treating brain diseases.
[0239] Experimental Example 9. Efficacy Evaluation in an MPTP-Induced Parkinson's Disease Mouse Model
[0240] Experimental Example 9.1. Experimental Preparation
[0241] All animal experiments described in this specification were approved by the Institutional Animal Care and Use Committee (IACUC) and conducted in accordance with the Ministry of Food and Drug Safety's guidelines for the care and use of laboratory animals.
[0242] Six-week-old C57BL / 6 male mice were purchased from Koatech (Korea). Mice were housed in groups of up to four per cage under a controlled temperature (22±1°C) and humidity (30–50%), with a normal light–dark cycle (08:00–20:00). Food and water were provided ad libitum. Mice were allowed to acclimate for 1 week before the start of the experiment.
[0243] The test drugs were administered to normal mice and a Parkinson's disease (PD) mouse model induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), and their efficacy was evaluated. For the compounds of the examples, the test drugs were prepared using 10% NMP, 40% PEG 400, and 50% DW (distilled water) as vehicles.
[0244] All values in the evaluation results are expressed as the mean ± standard error (SEM) and were statistically analyzed using one-way ANOVA with LSD (Least Significant Difference) post hoc analysis. The significance level of the evaluation results was determined according to the following criteria.
[0245] Significance level compared to G1 - *: p < 0.05, **: p < 0.01, ***: p < 0.001
[0246] Significance level compared to G2 - #: p < 0.05, ##: p < 0.01, ###: p < 0.001
[0247] Experimental Example 9.2. Experimental Design
[0248] Figure 3 is a schematic diagram of an efficacy experiment for an MPTP-induced PD mouse model.
[0249] Seven-week-old mice were divided into seven groups as shown in Table 9 below to generate an acute MPTP model and administer drugs: Control group + vehicle (G1), MPTP + vehicle (G2), MPTP + nilotinib 40 mg / kg (G3), MPTP + Example 3 2 mg / kg (G4), MPTP + Example 3 10 mg / kg (G5), MPTP + Example 3 50 mg / kg (G6), and MPTP + Example 2 50 mg / kg (G7). The test drugs were orally administered (PO) at 10 ml / kg once daily (QD) from day 1 to day 7. The acute MPTP model was performed on day 0 with the exception of the control group, in which all groups received MPTP at 2-hour intervals. .HCl (free base 20 mg / kg) was administered intraperitoneally (IP) four times. The control group received the same volume of 0.9% saline. The pole test was performed on day 4 (after training on days 2 and 3). All mice were euthanized on day 7, and their brains were collected.
[0250] During the study period, mice were weighed daily and examined for any abnormalities. If the overall health of the mice deteriorated significantly, they were euthanized and excluded from the study.
[0251] Group Individual Type Administration Drug Administration Method Dosage G112 Saline Delivery System PO, QD-G212 MPTP Delivery System PO, QD-G311 MPTP Nilotinib PO, QD 40 mg / kg G412 MPTP Example 3 PO, QD 2 mg / kg G512 MPTP Example 3 PO, QD 10 mg / kg G612 MPTP Example 3 PO, QD 50 mg / kg G711 MPTP Example 2 PO, QD 50 mg / kg
[0252] Experimental Example 9.3. Evaluation of the Efficacy of Improving Behavioral Defects
[0253] A vertical wooden pole (0.8 to 1 cm in diameter and 80 cm in length to provide a grip for the mouse) was placed on the floor of the cage and tested. The mice were trained on two consecutive days (days 2 and 3), and each training session consisted of three trials. On day 3 (day 4, the actual test day), the mice were placed at the end of the pole, and the total time it took for the mice to turn around at the top and reach the bottom of the pole was measured. The turn down (time it took for the mouse to turn its head down), climb down (time it took from the point where the mouse lowered its head to touching the floor), and the total time to touch the floor were recorded separately, and the graph in Figure 4 was obtained.
[0254] Figure 4 is a graph showing the results of a behavioral defect evaluation (pole test) for an MPTP-induced PD mouse model. In the pole test, it was confirmed that the group treated with MPTP (G2) took significantly longer to rotate (a in Figure 4), descend (b in Figure 4), and reach the ground (c in Figure 4) than the control group (G1). The groups treated with MPTP and the example compound (G4 to G7) showed a significant decrease in the time required to rotate compared to group G2. In particular, groups G4 and G5 showed a significant decrease in the rotation, descend, and ground reaching times. Through this, it was confirmed that the example compound significantly improved the behavioral defects.
[0255] Experimental Example 9.4. Evaluation of TH Staining Degree
[0256] To collect tissue samples for staining and analysis of histological sections, mice were euthanized with Zoletil. After cardiac blood collection, the remaining blood was perfused with phosphate-buffered saline (PBS). For half of the mice (n=6 / group), the brains were dissected into the striatum, substantia nigra, and the remainder of the brain, flash-frozen, and stored at -80°C. For the remaining mice (n=6 / group), the brains were isolated, fixed in 4% paraformaldehyde for 24 hours at 4°C, and then stored in 30% sucrose in phosphate-buffered saline (PBS) containing 0.02% sodium azide for 3 days at 4°C. Immunohistochemical sections were performed on brain samples embedded with OCT (Optimal Cutting Temperature) compound. Samples were sectioned at 20 μm thickness using a Leica CM1950 (Leica Microsystems, Germany) and stored in preservative solution at 4°C until staining with antibodies.
[0257] Tyrosine hydroxylase (TH) catalyzes the conversion of the amino acid L-tyrosine to L-3,4-dihydroxyphenylalanine (L-DOPA), a key factor in the biosynthesis of catecholamines, including dopamine (DA). Alterations in TH expression or activity significantly influence DA production, making it crucial for the pathogenesis of Parkinson's disease.
[0258] After staining the striatum and substantia nigra of the brain and mounting on microscope slides, the slides were washed with phosphate-buffered saline (PBS) containing 0.3% Triton X-100 and peroxidase block for 15 minutes at room temperature. The slides were washed three times with PBS containing 0.3% Triton X-100 and then blocked in a solution containing PBS, 5% normal goat serum, and 0.3% Triton X-100 for 1 hour at room temperature (RT). Tyrosine hydroxylase antibody was diluted 1:1000 and incubated overnight at 4°C. The slides were washed with PBS solution and incubated with secondary antibody for 1 hour at RT. The slides were washed with PBS solution, and the sections were placed in the solution for DAB (diaminobenzidine) reaction.
[0259] The DAB reaction was monitored for 2 to 3 minutes under a microscope. The slides were washed with PBS to stop the DAB reaction, dehydrated, and mounted using xylene. TH staining images were visualized using an Olympus microscope (Olympus, SZ61, BX51). The optical density (OD) values of positive TH staining were measured in the striatum and substantia nigra and analyzed using Image J software.
[0260] Figures 5a and 5b show the results of immunohistochemical analysis of TH staining in the striatum, and Figures 6a and 6b show the results of immunohistochemical analysis of TH staining in the substantia nigra. The TH level in the striatum and substantia nigra of the MPTP-treated group (G2) was significantly lower than that of the control group (G1). The striatal TH level in the nilotinib-treated group (G3) was significantly higher than that of G2. The groups treated with Example 3 or Example 2 showed significantly increased TH levels in both the striatum and substantia nigra compared to G2. In addition, the TH levels in the striatum in G5 (MPTP + 10 mg / kg Example 3) and G6 (MPTP + 50 mg / kg Example 3) and the TH levels in the substantia nigra in G5, G6, and G7 (MPTP + 50 mg / kg Example 2) were significantly higher than that of the control group (G1).
[0261] Experimental Example 9.6. Evaluation of dopamine-increasing efficacy
[0262] The amount of dopamine in the striatum and substantia nigra of the extracted brain tissue was measured through LC-MS / MS analysis using Agilent 1290 (LC) and SCIEX QTARP 6500 + (QQQ).
[0263] Figure 7 is a graph showing the dopamine levels by group in the striatum and substantia nigra of an MPTP-induced PD mouse model. Referring to Figure 7, the dopamine concentration significantly increased in both the striatum and substantia nigra in the 50 mg / kg group of Example 2, and in the substantia nigra in the 2 and 10 mg / kg groups of Example 3, compared to the MPTP-only group. This confirmed that the compound of the example significantly increased the dopamine level.
[0264] Experimental Example 10. Efficacy Evaluation in an α-Syn Transgenic Parkinson's Disease Mouse Model
[0265] Experimental Example 10.1. Experimental Preparation
[0266] mThy-1α-syn transgenic (α-syn TG; Line 61) females obtained from the University of California San Diego (UCSD), USA, were bred with C57BI / 6 X DBA / 2 F1 WT (wild type) males and raised at the Osong Medical Industry Promotion Foundation (KBIOHealth) Animal Center.
[0267] All mice were housed under a normal light-dark cycle (08:00–20:00) in a temperature-controlled (22±1°C) and humidity-controlled (30–50%) environment, with food and water provided ad libitum. Ear marking was performed at 15–21 days of age, and ear or tail samples were collected for genotyping by polymerase chain reaction (PCR). Tail samples were also collected at the end of the experiment for genotyping, if necessary.
[0268] The test drugs were administered to normal mice and α-Syn (alpha-synuclein) transgenic Parkinson's disease mouse models, and their efficacy was evaluated. For the compounds of the examples, the test drugs were prepared using 10% NMP, 40% PEG 400, and 50% DW as carriers.
[0269] Experimental Example 10.2. Experimental Design and Mouse Weight Changes
[0270] Figure 8 is a schematic diagram of an efficacy experiment on an α-Syn transgenic Parkinson's disease mouse model.
[0271] Mice aged 4 months were divided into 7 groups as shown in Table 10 below. The test drug was administered orally (PO) once daily (QD) at a dose of 5 mL / kg for 5 months from 4 to 9 months of age. Motor behavioral tests (beam test) and neurological scores (modified Irwin test) were performed at 4 months (before administration), 7 months, and 9 months of age. Tissue samples were collected after the final behavioral test. Body weights were measured once a week on the same day from 4 months of age until the end of the study. Mice with significantly worse overall health were excluded from the study.
[0272] Group Individual Type Administration Drug Administration Method Dosage G18WT---G28TG Delivery System PO, QD-G38TG Memantine PO, QD 10 mg / kg G48TG Example 3 PO, QD 2 mg / kg G58TG Example 3 PO, QD 10 mg / kg G68TG Example 3 PO, QD 50 mg / kg G78TG Example 2 PO, QD 2 mg / kg
[0273] Figure 9 is a graph showing group-specific body weight changes in α-Syn transgenic Parkinson's disease mouse models. Referring to Figure 9, the body weight of WT mice (G1) increased over time, whereas the weight gain in the TG group (G2-7) stagnated. The difference in body weight between WT and TG mice became apparent after approximately 21 to 22 weeks of age, and drug administration was found to have no significant effect on the body weight of TG mice.
[0274] Experimental Example 10.3. Neurological Behavioral Improvement Effect
[0275] At 4 months of age (baseline, before administration), 7 months, and 9 months of age, mice were observed for 1 to 2 minutes per mouse for neurological behaviors listed in Table 11 below. Neurological behavioral deficits, excluding the startle reflex, tail pinch, and righting reflex, were scored by direct observation of the mice in their cages. To test the startle reflex, a small remote control was used to produce a loud noise and behaviors such as jumping, freezing, and rapid eye blinking were observed. For the righting reflex, each mouse was removed from its cage and placed with its back facing the floor, allowing the mouse to right itself. The tail pinch reflex was tested by gently pinching the tip of the tail with forceps.
[0276] A score of 0 was assigned for normal characteristics such as motor activity or no abnormal characteristics, 1 for mild abnormalities, and 2 or 3 for severe abnormalities. The scores for all observed behaviors were added for each mouse, and the average of the added scores for each group was calculated.
[0277] #Neurological Score Index#Neurological Score Index1Head tremor16Seizure2Head twitch17Urine staining3Head bobbing18Lacrimation4Head searching19Salivation5Body tremor20Limb splay6Body twitch21Catalepsy7Tail tremor22Abnormal gait8Tail twitch23Tip toe walking9Straub tail24Slow, careful movement movements)10 Piloerection25 Excessive grooming11 Shallow respiration26 Circling, sniffing12 Flattened body posture27 Chewing13 Swollen face28 Loss of startle reflex (jumping, freezing, eye blinking)14 Ptosis29 Loss of righting reflex15 Irritability30 Loss of response to tail pinch
[0278] Figure 10 is a graph showing the neurological behavioral scores by group of α-Syn transgenic Parkinson's disease mouse models. At 4 and 7 months of age, the neurological scores (TG + transmitter) of G2 were significantly lower than those of G1. The groups administered Example 3 or Example 2 showed a significant decrease in the neurological scores of TG mice compared to G2. The neurological scores of groups G4 to G7 remained very low throughout the study period, confirming the absence of drug-induced neurological toxicity.
[0279] Experimental Example 10.4. Evaluation of the Efficacy of Improving Gait Errors (Beam Test)
[0280] The beam test (challenging beam traversal) was adopted according to the procedure described by Fleming et al. (J Neurosci, 24:9434-40, 2004). Motor ability was measured using a new beam test modified from the existing beam walking test. The beam was made of Plexiglas and consisted of four sections (each 25 cm, total length 1 m) with different widths. The beam was designed to start at 3.5 cm wide and gradually narrow to 0.5 cm × 1 cm. A 1 cm wide shelf was placed 1.0 cm below the upper surface of the beam.
[0281] Mice were trained to traverse the length of the beam, starting from the widest section and ending at the narrowest and most challenging section. The narrow end of the beam was designed to connect directly to the mouse's home cage. Mice were trained for two days before testing, all without a mesh grid. On the first day, mice were placed on the beam and given two assisted training sessions, where the home cage was placed close to the mouse. This encouraged forward movement along the beam. After two assisted training sessions, mice were able to traverse the entire length of the beam without assistance. On the first day of training, all mice completed five unassisted runs across the entire length of the beam. On the second day of training, mice were given five trials. On the day of testing, a mesh grid (1 cm square) of the appropriate width was placed on the beam surface, leaving approximately 1 cm of space between the grid and the beam surface to increase the difficulty. A shelf below provided support for mice when their limbs slipped on the grid and allowed them to assess compensatory motor strategies without having to use them to complete the test. A video was taken of a mouse crossing a grid-patterned beam five times in total.
[0282] Videotapes were analyzed by a researcher blinded to mouse genotype / group to determine slow-motion errors, and the number of steps taken and the time taken to cross the beam for each mouse were assessed across five trials. An error was counted when a limb (forelimb or hindlimb) crossed the grid and appeared between the grid and the beam surface during forward movement. Each mouse could slip up to four times per step. Each limb slip was scored individually to determine the error. For example, a mouse in which three limbs slipped off the grid in a single step was scored as an error score of 3, while a mouse in which only one limb slipped off the grid in a single step was scored as an error score of 1 for that step. Slips were not counted if the mouse did not move forward or if its head was turned to the left or right of the beam. The number of step errors and the time taken to cross the beam were measured across all five trials and averaged.
[0283] Figure 11 is a graph showing the results of gait error assessments by group in an α-Syn transgenic Parkinson's disease mouse model. Referring to Figure 11, Group G2 made significantly more errors while crossing the beam test compared to Group G1. The groups administered memantine (G3), Examples 3 (G4 to G6), or Example 2 (G7) showed a significant decrease in the number of gait errors compared to Group G2 at 7 and 9 months. This confirmed that the Example compounds improved behavioral errors.
[0284] Experimental Example 10.5. Evaluation of the Efficacy of Improving Dopaminergic Neurodegeneration
[0285] At 9 months of age, the measurement period was terminated by anesthetizing the mice and puncturing the heart according to IACUC guidelines. For tissue staining, the mice were transcardially perfused with 0.9% saline and then perfused with 4% paraformaldehyde until fixed. The brains were isolated and fixed in 4% paraformaldehyde at 4°C for 24 hours. Then, they were stored in 30% sucrose in PBS containing 0.02% sodium azide at 4°C for 3 days. Brain samples embedded in OCT compound were sectioned at 20 μm thickness using a Leica CM1950 (Leica Microsystems, Germany). The sections were stored in preservative at 4°C until staining with antibodies.
[0286] Brain tissues were washed three times with PBS for 10 minutes each while gently shaking the tissues. The tissues were then reacted for 1 hour at room temperature in a blocking buffer containing PBS, 10% normal goat serum, and 0.3% Triton X-100. The tissues were incubated overnight at 4°C with primary antibodies (Iba-1, TH) according to the antibodies and dilutions listed in the table below. After primary antibody incubation, the tissues were washed with PBS solution and reacted with secondary antibodies for 1 hour at room temperature. The sections were then washed three times with PBS solution for 10 minutes each and mounted on slides and coverslips using DAPI mounting solution (VECTASHIELD, #H1500).
[0287] Antibody source # cat dilution anti-tyrosine hydroxylase AbcamAb1121 / 1000 anti-Iba1 AbcamAb2833191 / 250
[0288] TH-stained brain tissues were imaged using an Olympus immunofluorescence microscope (Olympus, BZ21). The fluorescence intensity of the striatum was analyzed using Image J software.
[0289] Figures 12a and 12b are graphs and immunofluorescence analysis images showing the results of the evaluation of the efficacy of improving dopaminergic neurodegeneration by group in an α-Syn transgenic Parkinson's disease mouse model. Referring to Figures 12a and 12b, the TH staining intensity of the striatum of group G2 tended to be lower than that of group G1. The TH staining intensity of the groups administered Example 3 or Example 2 (groups G4 to G7), but not memantine, was significantly higher than that of group G2. The TH staining intensity of group G7 (TG + Example 2) was also significantly higher than that of group G2. Thus, it was confirmed that the compound of the example could significantly improve dopaminergic neurodegeneration.
[0290] Experimental Example 10.6. Evaluation of Microglial Reduction Efficacy
[0291] To assess cortical microgliosis, Iba-1-stained brain tissue from Experimental Example 10.5 was imaged using an Olympus immunofluorescence microscope (Olympus, BZ21). Each marker was manually counted for Iba1 quantification.
[0292] Figures 13a and 13b are graphs and immunofluorescence analysis images showing the results of the evaluation of the microglial cell reduction efficacy by group in the α-Syn transgenic Parkinson's disease mouse model. Referring to Figures 13a and 13b, the number of Iba-1 positive cells in the cerebral cortex was significantly reduced in the memantine (G3), Example 3 2 mg / kg and 10 mg / kg (G4 and G5), and Example 2 2 mg / kg (G7) administration groups. This confirmed that the Example compound significantly reduced microglial cells.
[0293] Experimental Example 11. Efficacy Evaluation in a SOD1 G93A Transgenic Amyotrophic Lateral Sclerosis Mouse Model
[0294] Experimental Example 11.1. Experimental Preparation
[0295] Experimental F1 mice were generated by crossing male G93A SOD1 (high-copy SOD1-G93A, 25 TG copies of G1H, stock no. 002726) from the Jackson Laboratory with females from the B6SJL strain background (non-carrier, WT). All mice were housed in a temperature-controlled (22±1°C) and humidity-controlled (30–50%) environment under a normal light–dark cycle (08:00–20:00) and provided with food and water ad libitum. Ears were marked at 15–21 days of age, and ear or tail samples were collected for PCR analysis for genotyping. Tail samples were also collected at the end point for genotyping, if necessary.
[0296] The test drugs were administered to normal mice and SOD1 G93A transgenic amyotrophic lateral sclerosis (ALS) mouse models, and their efficacy was evaluated. For the compounds of the examples, the test drugs were prepared using 10% NMP, 40% PEG 400, and 50% DW as carriers.
[0297] Experimental Example 11.2. Experimental Design
[0298] Figure 14 is a schematic diagram of an efficacy experiment on a SOD1 G93A transgenic ALS mouse model.
[0299] Eight-week-old mice were divided into three groups as shown in Table 13 below. The test drugs were administered orally (PO) once daily (QD) at a dose of 5 mL / kg from 8 weeks of age until death. Body weights were measured weekly, and disease scores were measured daily from 8 weeks until death. Motor behavior tests (grip strength) and neurological score tests (modified Irwin test) were performed at 9, 11, 13, 15, 17, 19, and 21 weeks, respectively. Mice were monitored daily for survival. Mice were excluded from the study if their overall health deteriorated significantly.
[0300] Group N type administration drug administration method administration amount G112WT---G212TG delivery system PO, QD-G312TG Example 3 PO, QD 30 mg / kg
[0301] Figure 15 is a graph showing group-specific body weight changes in the SOD1 G93A transgenic ALS mouse model. Referring to Figure 15, the body weight of the Tg group (G2) was significantly lower than that of the WT group (G1). On the other hand, there was no significant difference between the TG (G2) and drug-treated groups (G3), confirming that the example compound did not significantly reduce body weight.
[0302] Experimental Example 11.3. Evaluation of Neurological Behavioral Improvement Efficacy
[0303] Neurological dysfunction behaviors were observed for 1 to 2 minutes per mouse at 9, 11, 13, 15, 17, 19, and 21 weeks of age using the same method as in Experimental Example 10.3.
[0304] Figure 16 is a graph of the neurological scores by group of the SOD1 G93A transgenic ALS animal model. Referring to Figure 16, the neurological score of the WT group (G1) was very low, less than 1, throughout the study period. From the 13th week onwards, the neurological score of the TG group was significantly higher than that of the G1 group. From the 19th week after birth, the group treated with Example 3 (G3) showed a significant decrease in neurological score compared to G2. This confirmed that the Example compound significantly improved neurological behavior.
[0305] Experimental Example 11.4. Evaluation of Disease Symptom Improvement Efficacy
[0306] Mice were evaluated for disease symptoms starting at 8 weeks of age using a neurological scoring system developed by the ALS Therapy Development Institute (ALSTDI). Scoring was performed for both hind limbs according to the criteria in Table 14 below.
[0307] Score Criteria 0 When hanging by the tail, the hind legs are fully extended away from the lateral center line 1 When hanging by the tail, the hind legs shake 2 When hanging by the tail, the hind feet touch each other 3 When walking, the animal stumbles and falls 4 When walking, one or both hind legs fall off 5 When the animal cannot walk (when the animal is placed on its back, the animal cannot right itself within 30 seconds)
[0308] Figure 17 is a graph showing changes in disease scores by group in the SOD1 G93A transgenic ALS mouse model. Referring to Figure 17, the disease onset scores of the TG groups (G2 and G3) significantly increased compared to the WT group (G1), and the difference became noticeable at approximately 15 weeks of age. The group (G3) treated with Example 3 showed a lower disease symptom score compared to G2 throughout the observation period, and significantly decreased at 20 weeks. Through this, it was confirmed that the Example compound significantly improved disease symptoms.
[0309] Experimental Example 11.5. Evaluation of the efficacy of improving grip strength
[0310] Grip strength was measured on mice aged 9, 11, 13, 15, 17, 19, and 21 weeks. Mice were placed on a grip strength measuring device (San Diego Instruments, San Diego, CA, USA) with their forepaws grasping a small mesh handle. The mouse was then lowered onto the platform and the handle was slowly pulled with its tail until it released the grip. The device automatically measured the grip strength in grams. Five scores were continuously recorded per mouse per session.
[0311] Figure 18 is a graph showing changes in grip strength by group in the SOD1 G93A transgenic ALS mouse model. Referring to Figure 18, grip strength in the TG group generally decreased over time and was significantly lower than that of group G1. The group (G3) treated with Example 3 showed a tendency for grip strength to increase compared to group G2, and grip strength significantly increased from week 19. This confirmed that the Example compound significantly improved grip strength.
[0312] Experimental Example 11.1. Evaluation of Survival Rate Improvement Efficacy
[0313] Mice were monitored daily for survival. The survival ages of the mice were recorded and displayed in Kaplan Meier survival plots.
[0314] Figure 19 is a graph showing the survival rates by group of the SOD1 G93A transgenic ALS mouse model. Referring to Figure 19, the survival rate of the TG group began to decline from approximately 110 to 120 days after birth, and the group (G3) treated with Example 3 showed a trend of improved survival rate compared to group G2, although not significantly. This confirmed that the Example compound improved survival rate.
[0315] Experimental Example 12. Efficacy Evaluation in a Reserpine-Induced Fibromyalgia Rat Model
[0316] Experimental Example 12.1. Experimental Preparation
[0317] Six-week-old male Sprague Dawley (SD) rats were used. All rats were housed under a normal light-dark cycle (08:00-20:00) in a temperature-controlled (22±1℃) and humidity-controlled (30-50%) environment, and food and water were provided ad libitum.
[0318] The test drugs were administered to normal rats and a reserpine-induced fibromyalgia rat model, and their efficacy was evaluated. For the compounds of the examples, the test drugs were prepared using 10% NMP, 40% PEG 400, and 50% DW as carriers.
[0319] Experimental Example 12.2. Experimental Design
[0320] Figure 20 is a schematic diagram of an efficacy experiment on a reserpine-induced fibromyalgia rat model.
[0321] The generation and drug administration of the reserpine-induced fibromyalgia model were performed by dividing 6-week-old male SD rats into 6 groups as shown in Table 15 below: control group (G1), reserpine + vehicle (G2), reserpine + gabapentin 50 mg / kg (G3), reserpine + Example 2 3 mg / kg (G4), 10 mg / kg (G5), and 30 mg / kg (G6). To create the rat fibromyalgia model, reserpine (Sigma-aldrich, 1 mg / kg) dissolved in 0.5% acetic acid was administered subcutaneously once for 3 days starting 3 days before the start of the experiment. From day 1, the vehicle, gabapentin, and Example 2 were administered intraperitoneally (IP) or orally (PO) 2 hours before the experiment once daily (QD).
[0322] Group Individual Type Administration Drug Administration Method Administration Dosage G16 Saline---G26 Reserpine Delivery System PO, QD-G36 Reserpine Gabapentin IP, QD 50 mg / kg G46 Reserpine Example 2 PO, QD 3 mg / kg G56 Reserpine Example 2 PO, QD 10 mg / kg G66 Reserpine Example 2 PO, QD 30 mg / kg
[0323] Experimental Example 12.3. Evaluation of Pain Relief Efficacy
[0324] The right hindpaw tactile response test (von Frey test) was performed five times (before fibromyalgia model creation, and on days 1, 2, 4, and 6 after model creation). Rats were allowed to acclimate to the environment for 30 minutes before all behavioral tests, and all experimenters performing the behavioral tests were blinded to drug administration information. Baseline measurements were performed on all rats by performing the von Frey test before model creation. Rats were placed on a wired mesh and placed in a transparent plastic box (20 x 20 x 14 cm). To assess mechanical allodynia, von Frey filaments (ascending weights: 0.4, 0.6, 1.4, 2, 4, 6, 8, and 15 g, North Coast) were applied to the center of the right hindpaw to measure paw withdrawal thresholds.
[0325] Figure 21 is a graph showing the results of an evaluation of pain-improving efficacy in a reserpine-induced fibromyalgia rat model. Compared to the control group (G1), the reserpine-treated group (G2) showed higher sensitivity, and after model creation, the gabapentin-treated group (G3) and Example 2-treated groups (G4 to G6) showed gradual improvement in sensitivity over time. Example 2 showed a tendency for recovery in a dose-dependent manner, and showed significant efficacy at 30 mg / kg. This confirmed that the compound of the example significantly improved pain.
[0326] Experimental Example 13. Efficacy Evaluation in a CDAHFD-Induced Nonalcoholic Steatohepatitis Mouse Model
[0327] Experimental Example 13.1. Experimental Preparation
[0328] Three-week-old C57BL / 6 male mice (Koatech, Korea) were purchased. Mice were housed in groups of up to five per cage under a controlled temperature (22±1°C) and humidity (30–50%), with a normal light–dark cycle (08:00–20:00). Food and water were provided ad libitum. Mice were allowed to acclimate for 1 week before the start of the experiment.
[0329] The test drugs were administered to normal mice and CDAHFD (A choline-deficient, L-amino acid-defined, high-fat diet)-induced non-alcoholic steatohepatitis (NASH) mouse models, and their efficacy was evaluated. For the compounds of the examples, the test drugs were prepared using 10% NMP, 40% PEG 400, and 50% DW as carriers.
[0330] CDAHFD is a high-fat diet containing 0.1% methionine and 60 kcal% fat, and is deficient in choline. C57BL / 6J mice fed CDAHFD rapidly develop steatohepatitis with fibrosis over a short period of time.
[0331] Experimental Example 13.2. Experimental Design
[0332] Figure 22 is a schematic diagram of an efficacy experiment on a CDAHFD-induced non-alcoholic steatohepatitis mouse model.
[0333] The CDAHFD-induced NASH model was created and drug administration was performed by dividing 3-week-old C57BL / 6 male mice into 7 groups as shown in Table 16 below. The control group (G1) was fed a standard diet and water. Groups G2 to G7 were fed a CDAHFD (Research Diet Inc, #A06071302) diet for 4 and 8 weeks, respectively. Except for the control group, each group was orally administered the carrier, selonsultib 30 mg / kg, Example 3 10 mg / kg, Example 3 30 mg / kg, Example 2 10 mg / kg, and Example 2 30 mg / kg once daily (QD) from the age of 5 weeks.
[0334] Group Number of individuals Diet Administration Drug Administration method Administration amount G110 Standard feed --- G210 CDAHFD Delivery system PO, QD-G310 CDAHFD Selonsertib PO, QD 30 mg / kg G410 CDAHFD Example 3 PO, QD 10 mg / kg G510 CDAHFD Example 3 PO, QD 30 mg / kg G610 CDAHFD Example 2 PO, QD 10 mg / kg G710 CDAHFD Example 2 PO, QD 30 mg / kg
[0335] Experimental Example 13.3. Evaluation of the Efficacy of Improving Liver Fibrosis
[0336] Picrosirius red staining was used for histological visualization of collagen fibers. The efficacy in improving liver fibrosis was evaluated through histopathological analysis.
[0337] For each group of mice, three sections of liver fixed with 4% paraformaldehyde (PFA) were prepared as paraffin blocks. The paraffin blocks were sectioned at 5 μm thickness (Histocore AUTOCUT R, Leica Microsystems, Germany), mounted on silane-coated slides (MUTO, JPN), and stored until staining.
[0338] Paraffin was removed from the slides using xylene, and the slides were rehydrated and washed. The slides were stained with picrosirius red solution (ab150681, Abcam, UK) and rinsed with acetic acid. The slides were dehydrated and washed with alcohol and xylene, and then mounted. For each section, two images of different areas were taken using a microscope (Axioscan7, Zeiss, Germany). The area of fibrosis was measured as a percentage of the total area using Image J software.
[0339] Figures 23a and 23b are graphs and images of the Picrosirius red staining area ratio in the liver of a CDAHFD-induced non-alcoholic steatohepatitis mouse model. Referring to Figures 23a and 23b, the CDAHFD group had a significantly higher relative area stained with Picrosirius red compared to Group G1, indicating that the NASH model was formed appropriately. The Picrosirius red staining area was significantly reduced in the comparative drug selonsultib (G3) and Examples 3 (G4 and G5) and Example 2 (G6 and G7), and the most improved efficacy was confirmed in the Example 2 30 mg / kg administration group after 4 weeks of CDAHFD diet. This confirmed that the Example compound significantly improved liver fibrosis.
Claims
1. A compound represented by the following chemical formula 1, a stereoisomer thereof, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof: [Chemical Formula 1] In the above chemical formula 1, is unsubstituted or substituted phenyl or unsubstituted or substituted C 3-8 It is cycloalkenyl, The above substituted phenyl and substituted C 3-8 Each cycloalkenyl is independently C 1-6 Alkyl, C 1-6 substituted with alkoxy or halogen; R1, R2 and R3 are each independently H, C 1-6 Alkyl, halogen, C 3-6 Cycloalkyl or haloC 1-6 It's alkyl.
2. In paragraph 1, is unsubstituted or substituted phenyl or unsubstituted or substituted C 5-8 It is cycloalkenyl, The above substituted phenyl and substituted C 3-8 Each cycloalkenyl is independently C 1-3 Alkyl, C 1-3 substituted with alkoxy or halogen; R1, R2 and R3 are each independently H, C 1-3 Alkyl, halogen, C 3-6 Cycloalkyl or haloC 1-3 alkyl, A compound, a stereoisomer thereof, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof.
3. In paragraph 1, C containing one phenyl or double bond 5-8 It is cycloalkenyl; R1 is C 3-6 It is cycloalkyl, R2 is C 1-3 It is alkyl, R3 is a halogen, A compound, a stereoisomer thereof, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof.
4. In paragraph 1, C containing phenyl or one double bond 5-8 It is cycloalkenyl; R1 is cyclopropyl, R2 is methyl, R3 is fluoro, A compound, a stereoisomer thereof, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof.
5. In paragraph 1, The compound represented by the above chemical formula 1 is characterized in that it is any one compound selected from the group of compounds below. A compound, a stereoisomer thereof, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof: <1> N-(6-(1H-Benzo[d][1,2,3]triazol-1-yl)pyridin-2-yl)-5-(4-cyclopropyl-1H-imidazol-1-yl)-2-fluoro-4-methylbenzamide; <2> 5-(4-Cyclopropyl-1H-imidazol-1-yl)-N-(6-(5,6-dihydrocyclopenta[d][1,2,3]triazol-1(4H)-yl)pyridin-2-yl)-2-fluoro-4-methylbenzamide; <3> 5-(4-Cyclopropyl-1H-imidazol-1-yl)-2-fluoro-4-methyl-N-(6-(4,5,6,7-tetrahydro-1H-benzo[d][1,2,3]triazol-1-yl)pyridin-2-yl)methylbenzamide; <4> 5-(4-cyclopropyl-1H-imidazol-1-yl)-2-fluoro-4-methyl-N-(6-(5,6,7,8-tetrahydrocyclohepta[d][1,2,3]triazol-1(4H)-yl)pyridin-2-yl)benzamide; and <5> 5-(4-Cyclopropyl-1H-imidazol-1-yl)-2-fluoro-N-(6-(4,5,6,7,8,9-hexahydro-1H-cycloocta[d][1,2,3]triazol-1-yl)pyridin-2-yl)-4-methylbenzamide.
6. In paragraph 1, The compound is characterized by inhibiting ASK1, a stereoisomer thereof, a solvate thereof, a hydrate thereof or a pharmaceutically acceptable salt thereof.
7. As shown in the following reaction formula 1, A method for producing a compound represented by chemical formula 1 of claim 1, comprising the step of producing a compound represented by chemical formula 1 by reacting a compound represented by chemical formula 2 with a compound represented by chemical formula 3: [Reaction Formula 1] In the above reaction formula 1 , R1, R2, and R3 are as defined in chemical formula 1 of the first paragraph.
8. A pharmaceutical composition containing a compound represented by the chemical formula 1 of paragraph 1, a stereoisomer thereof, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof as an active ingredient.
9. A pharmaceutical composition for preventing or treating an ASK1-related disease, comprising a compound represented by chemical formula 1 of paragraph 1, a stereoisomer thereof, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof as an active ingredient.
10. A pharmaceutical composition according to claim 9, wherein the ASK1-related disease includes a neurodegenerative disease, a cardiovascular disease, an autoimmune disease, or a liver disease.
11. In paragraph 10, A pharmaceutical composition characterized in that the neurodegenerative disease is at least one selected from the group consisting of Alzheimer's disease, hippocampal sclerosis, frontotemporal dementia (FTD), frontotemporal lobar degeneration (FTLD), Huntington's disease, corticobasal degeneration, amyotrophic lateral sclerosis, spinal muscular atrophy, motor neuron disease, inclusion body myositis, Parkinson's disease, dementia with Lewy bodies, Lewy body disease, multiple system atrophy, progressive supranuclear palsy, Pick's disease, prion disease, traumatic brain injury, ischemic and hemorrhagic stroke, cerebral ischemia, hypoxia, and glutamate neurotoxicity.
12. In paragraph 10, A pharmaceutical composition, characterized in that the cardiovascular disease is at least one selected from the group consisting of heart failure, ischemia, recurrent ischemia, myocardial infarction, arrhythmia, acute coronary syndrome, diabetes, atherosclerosis, and intermittent claudication.
13. In paragraph 10, A pharmaceutical composition, characterized in that the autoimmune disease is at least one selected from the group consisting of rheumatoid arthritis, fibromyalgia, systemic lupus erythematosus, multiple sclerosis, diabetes, systemic sclerosis, Graves' disease, Guillain-Barré syndrome, myasthenia gravis, psoriasis, Crohn's disease, ulcerative colitis, optic neuritis, and Sjogren's syndrome.
14. In paragraph 10, A pharmaceutical composition, characterized in that the liver disease is at least one selected from the group consisting of non-alcoholic fatty liver disease (NASH), alcoholic fatty liver disease, liver fibrosis, liver cancer, hepatotoxicity, cholestasis, cirrhosis, hepatic ischemia, liver abscess, hepatic coma, and hepatic atrophy.
15. A method for preventing or treating an ASK1-related disease, comprising administering to a subject a compound of any one of claims 1 to 6, or a solvate, stereoisomer, or pharmaceutically acceptable salt thereof.
16. Use of a compound according to any one of claims 1 to 6, a solvate, stereoisomer or pharmaceutically acceptable salt thereof, for the prevention or treatment of ASK1-related diseases.
17. Use of a compound according to any one of claims 1 to 6, a solvate, stereoisomer or pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the prevention or treatment of ASK1-related diseases.
Citation Information
Patent Citations
Apoptosis signal-regulating kinase inhibitor
WO2013112741A1
ASK1 inhibitor and application thereof
CN110698471A
Crystal form of benzoylaminopyridine derivative, and application thereof
CN110922407A
Aromatic heterocyclic amide compounds and uses thereof
CN113831323A
Crystal form as ask1 inhibitor, preparation method therefor, and application thereof
WO2020015721A1
